Acting as your CMO, strategic and operational, tailored to your needs
To focus resources on tumors with the highest potential for PoC and rule out early costly clinical dead ends
F: +41 79 624 79 55
M: a.rinaldi@medexpansion.ch
My structured sequential analysis bridges cell-stage results and tomorrow’s clinical reality :
Years Experienced
Start-up interactions
Welcome to my Clinical Dev Blog, a repository for my LinkedIn posts, 1‑minute videos and slide carousels.
Here I share cutting-edge, experience‑based insights on oncology clinical development, practical ideas to help you de‑risk projects, speed up trials and reach phase 2 PoC faster
In oncology, standards of care evolve rapidly. MEDExpansion explains why clinical strategy must anticipate future benchmarks from the earliest development phases
MEDExpansion explores how early strategic positioning can strengthen oncology clinical trials and anticipate evolving standards of care throughout development
MEDExpansion explains why defining the right medical need early is essential to build a strong oncology development strategy and guide clinical decision-making
ADCs were designed to selectively kill biomarker-positive cancer cells, but real-world results are complex. Learn why early clinical analysis is key to balancing efficacy, biomarker
